276 related articles for article (PubMed ID: 37685606)
1. Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review.
Khanam R; Faiman B; Batool S; Najmuddin MM; Usman R; Kuriakose K; Ahmed A; Rehman MEU; Roksana Z; Syed Z; Anwer F; Raza S
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685606
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
[TBL] [Abstract][Full Text] [Related]
3. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
Sanchez L; Dardac A; Madduri D; Richard S; Richter J
Ther Adv Hematol; 2021; 12():2040620721989585. PubMed ID: 33796236
[TBL] [Abstract][Full Text] [Related]
4. The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
Ghanem B; Shi L
BioDrugs; 2022 Nov; 36(6):773-780. PubMed ID: 36167952
[TBL] [Abstract][Full Text] [Related]
5. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
6. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
Ray U; Orlowski RZ
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111346
[TBL] [Abstract][Full Text] [Related]
8. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
Front Immunol; 2022; 13():991092. PubMed ID: 36119032
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.
Holstein SA; Grant SJ; Wildes TM
J Clin Oncol; 2023 Sep; 41(27):4416-4429. PubMed ID: 37471687
[TBL] [Abstract][Full Text] [Related]
10. Toxicity of CAR T-Cell Therapy for Multiple Myeloma.
Afrough A; Abraham PR; Turer L; Kaur G; Sannareddy A; Hansen DK; Anderson LD
Acta Haematol; 2024 May; ():1-15. PubMed ID: 38718775
[TBL] [Abstract][Full Text] [Related]
11. Current progress of CAR-T-cell therapy for patients with multiple myeloma.
Nakashima T; Kagoya Y
Int J Hematol; 2024 May; ():. PubMed ID: 38777913
[TBL] [Abstract][Full Text] [Related]
12. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma.
Midha S; Hartley-Brown MA; Mo CC; Hossain S; Nadeem O; O'Donnell EK; Bianchi G; Sperling AS; Laubach JP; Richardson PG
Expert Opin Drug Saf; 2023; 22(11):1049-1071. PubMed ID: 37906232
[TBL] [Abstract][Full Text] [Related]
13. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Anderson LD
Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
[TBL] [Abstract][Full Text] [Related]
14. Rethinking mechanisms of neurotoxicity with BCMA directed therapy.
Mohyuddin GR; Banerjee R; Alam Z; Berger KE; Chakraborty R
Crit Rev Oncol Hematol; 2021 Oct; 166():103453. PubMed ID: 34461271
[TBL] [Abstract][Full Text] [Related]
15. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Firestone RS; Socci ND; Shekarkhand T; Zhu M; Ge Qin W; Hultcrantz ML; Mailankody S; Tan CR; Korde N; Lesokhin AM; Hassoun H; Shah UA; Maclachlan KH; Rajeeve S; Landau HJ; Scordo M; Shah GL; Lahoud OB; Giralt SA; Murata K; Usmani SZ; Chung DJ
Blood; 2024 May; ():. PubMed ID: 38728378
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.
Sharma P; Kanapuru B; George B; Lin X; Xu Z; Bryan WW; Pazdur R; Theoret MR
Clin Cancer Res; 2022 May; 28(9):1759-1764. PubMed ID: 35046063
[TBL] [Abstract][Full Text] [Related]
17. Timing of Toxicities and Non-relapse Mortality Following CAR T Therapy in Myeloma.
Wesson W; Dima D; Suleman N; Saif MSI; Tabak C; Logan E; Davis JA; McGann M; Furqan F; Mohan M; Rashid A; Abdallah AO; Ullah F; Shune L; Mushtaq MU; Raza S; McGuirk J; Hamadani M; Anwer F; Hashmi H; Ahmed N
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38871056
[TBL] [Abstract][Full Text] [Related]
18. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
19. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
Martino M; Paviglianiti A
Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948
[No Abstract] [Full Text] [Related]
20. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]